We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Calcium Binder Use for Kidney Disease Questioned

By HospiMedica International staff writers
Posted on 29 Jul 2013
A new study challenges the common clinical practice of prescribing high doses of calcium to patients with chronic kidney disease (CKD).

Researchers at the University of Toronto (ON, Canada) and the University of Alberta (Edmonton, Canada) conducted a systematic review of randomized and nonrandomized trials that compared outcomes between patients with CKD taking calcium-based phosphate binders, with those taking non-calcium-based binders. More...
The researchers identified all articles published in any language after Aug 1, 2008, up until Oct 22, 2012, by searching Medline, Embase, International Pharmaceutical Abstracts, Cochrane Central Register of Controlled Trials, and Cumulative Index to Nursing and Allied Health Literature.

In all, the researchers identified 847 reports; an analysis of the 11 randomized, controlled trials involving 4,622 patients which met the inclusion criteria showed that patients assigned to non-calcium-based binders, such as sevelamer or lanthanum, had a 22% reduction in all-cause mortality compared with those assigned to calcium-based phosphate binders, as well as reduced calcification of coronary arteries. The study was published early online on July 19, 2013, in the Lancet.

“Doctors commonly prescribe calcium supplements to prevent elevated phosphate levels, which can damage the body, but a growing number of studies have shown calcium supplements may actually increase the risk of heart disease,” said lead author Sophie Jamal, MD, of the University of Toronto. “Our study validates these claims and, for the first time, shows the long-term consequences of taking calcium supplements can be dangerous for patients with kidney disease.”

“What we can say is that the risk of death is lower in those taking non-calcium-based treatments; what we don't know is the exact mechanism of this finding and whether it is that calcium is bad, or that sevelamer and lanthanum are good,” added senior author Ross Tsuyuki, MD, of the University of Alberta. “Some researchers and physicians have been saying for years that kidney disease patients need to get off calcium. Now we think our review shows there is much more solid evidence to argue for that change to clinical practice.”

Phosphate binders (calcium-based and calcium-free) are recommended to lower serum phosphate and prevent hyperphosphatemia in patients with CKD. Calcium binds to the phosphate in the body, eliminating it via the kidneys to the urine. Sevelamer or lanthanum can also get rid of phosphate in the body, but are much more expensive, costing up to 100 times more than calcium.

Related Links:

University of Toronto
University of Alberta



New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
X-Ray Generator
Advantage Plus Generators
New
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The new Cora Torqueable Microcatheters expand our coronary portfolio supporting patients with coronary artery disease (photo courtesy of Reflow Medical)

Torqueable Microcatheters Enhance Navigation in Complex Coronary Lesions

Interventional cardiologists frequently encounter tortuous vessels and heavily calcified or fibrotic coronary lesions that complicate guidewire control and device delivery. Stable, predictable torque and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.